Related Experiment Video
Updated: Apr 17, 2026
11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
19.9K
Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT2 Receptor Ligands
Charlotta Wallinder1, Christian Sköld1, Milad Botros2
1Organic Pharmaceutical Chemistry, Department of Medicinal Chemistry, BMC, Uppsala University , SE-751 23 Uppsala, Sweden.
ACS Medicinal Chemistry Letters
|February 21, 2015
Summary
Structural modifications to drug-like molecules can alter their function. Migrating a side chain in an AT2 receptor antagonist transformed it into an agonist, highlighting the importance of substituent positioning.
Area of Science:
- Medicinal Chemistry
- Pharmacology
Background:
- The angiotensin II type 2 receptor (AT2) is a target for various therapeutic applications.
- Selective drug-like agonists and antagonists for the AT2 receptor are crucial for research and drug development.
Purpose of the Study:
- To investigate the structure-activity relationship of AT2 receptor modulators.
- To explore how structural modifications, specifically side chain migration, affect the agonist/antagonist activity of AT2 receptor ligands.
Main Methods:
- Synthesis of novel biphenyl derivatives based on known AT2 receptor ligands.
- Pharmacological evaluation of synthesized compounds to determine their activity at the AT2 receptor.
Main Results:
- A previously identified AT2 receptor antagonist (compound 4) was successfully transformed into an agonist (compound 6) through the migration of its isobutyl group.
- This transformation demonstrates that the relative positioning of the methylene imidazole and isobutyl substituents is critical for determining AT2 receptor activity.
Conclusions:
- The precise placement of functional groups significantly influences the pharmacological profile of AT2 receptor ligands.
- Understanding these structure-activity relationships can guide the design of novel AT2 receptor agonists and antagonists.
Related Concept Videos
01:29The Two-State Receptor Model
3.6K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
3.6K
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
4.2K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
4.2K
01:29Drug-Receptor Interactions
8.5K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
8.5K
00:49Ligand Binding and Linkage
6.0K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
6.0K
01:31Adrenergic Receptors: ɑ Subtype
3.4K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.4K
01:25Drug-Receptor Interaction: Agonist
4.9K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.9K